Cargando…

Angiotensin II in vasodilatory shock: lights and shadows

Detalles Bibliográficos
Autores principales:	Antonucci, Elio, Agosta, Sara, Sakr, Yasser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686834/ https://www.ncbi.nlm.nih.gov/pubmed/29137677 http://dx.doi.org/10.1186/s13054-017-1869-9

Ejemplares similares

Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?
por: Buchtele, Nina, et al.
Publicado: (2018)

Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series
por: Zangrillo, Alberto, et al.
Publicado: (2020)

Angiotensin II: a new therapeutic option for vasodilatory shock
por: Bussard, Rachel L, et al.
Publicado: (2018)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Vasopressin and terlipressin in adult vasodilatory shock
por: Polito, Angelo, et al.
Publicado: (2012)

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
por: Tumlin, James A., et al.
Publicado: (2018)

How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review
por: Semedi, Bambang Pujo, et al.
Publicado: (2023)

Angiotensin II in ECMO patients: a word of caution
por: Antonucci, Elio, et al.
Publicado: (2019)

Speckle tracking echocardiography: another step towards early detection of septic myocardial dysfunction?
por: Antonucci, Elio, et al.
Publicado: (2016)

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients
por: Bailey, Dwight M., et al.
Publicado: (2019)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Vasopressin in vasodilatory shock: is the heart in danger?
por: Hauser, Balázs, et al.
Publicado: (2008)

Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019–Induced Vasodilatory Shock: A Retrospective Matched Cohort Study
por: Leisman, Daniel E., et al.
Publicado: (2020)

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
por: Wieruszewski, Patrick M., et al.
Publicado: (2023)

Advances in Vasodilatory Shock: A Concise Review
por: Lahiry, Sandeep, et al.
Publicado: (2019)

Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series
por: Tezel, Oguzhan, et al.
Publicado: (2023)

Vasopressin in vasodilatory shock: hemodynamic stabilization at the cost of the liver and the kidney?
por: Bracht, Hendrik, et al.
Publicado: (2007)

Risk factors for severe vasodilatory shock after cardiac surgery
por: Almeida, J, et al.
Publicado: (2015)

Vasopressin in pediatric vasodilatory shock: a multicentred randomized controlled trial
por: Choong, K, et al.
Publicado: (2009)

Refractory vasodilatory shock secondary to metformin overdose supported with VA ECMO()
por: Ives Tallman, Crystal, et al.
Publicado: (2021)

Lights and Shadows
Publicado: (1897)

Vasopressin in vasodilatory shock: ensure organ blood flow, but take care of the heart!
por: Dünser, Martin W, et al.
Publicado: (2006)

Vasopressin for the treatment of vasodilatory shock: an ESICM systematic review and a meta-analysis
por: Polito, A, et al.
Publicado: (2011)

Early norepinephrine decreases fluid and ventilatory requirements in pediatric vasodilatory septic shock
por: Ranjit, Suchitra, et al.
Publicado: (2016)

Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
por: Bendjelid, Karim
Publicado: (2020)

The Hepatitis B Vaccine and Celiac Disease: More Lights Than Shadows?
por: Vitaliti, Giovanna, et al.
Publicado: (2013)

VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK
por: Priyanka, Priyanka, et al.
Publicado: (2022)

Angiotensin in ECMO patients with refractory shock
por: Ostermann, Marlies, et al.
Publicado: (2018)

Angiotensin II in septic shock
por: Corrêa, Thiago D, et al.
Publicado: (2015)

Gene Expression Scoring of Immune Activity Levels for Precision Use of Hydrocortisone in Vasodilatory Shock
por: Yao, Lijing, et al.
Publicado: (2022)

Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study
por: Naoum, Emily E., et al.
Publicado: (2022)

Virtual Shadowing - at the Forefront of Clinical Experience, or Merely a Shadow? [Letter]
por: Rathore, Zainab, et al.
Publicado: (2023)

Lights and Shadows in Hepatic Encephalopathy Diagnosis
por: Amodio, Piero, et al.
Publicado: (2021)

"Vasopressor Support Sparing Strategies": a Concept to be Incorporated as a Paradigm in the Treatment of Vasodilatory Shock
por: Evora, Paulo Roberto B., et al.
Publicado: (2019)

Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis
por: Zhao, Cong-Cong, et al.
Publicado: (2022)

Hyponatremia in a Patient With Vasodilatory Shock Due to Overdose of Antihypertensive Medications: A Case Report
por: Rasheed, Abdul Hannan A, et al.
Publicado: (2023)

The use of angiotensin II in distributive shock
por: Chawla, Lakhmir S., et al.
Publicado: (2016)

Aging impairs vasodilatory responses in rats
por: Kim, Soon Yul, et al.
Publicado: (2011)

Reply to ‘Aortic valve surgery and left ventricular assist device: lights and shadows’
por: Veenis, Jesse F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u9vfif8bm6nd8jqj7iqg7vj247